Bristol-Myers Squibb Company
HETEROBICYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES

Last updated:

Abstract:

Compounds having the following formula (I), or a stereoisomer or pharmaceutically-acceptable salt thereof, where all substituents are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN.alpha., by acting on Tyk-2 to cause signal transduction inhibition. ##STR00001##

Status:
Application
Type:

Utility

Filling date:

27 Oct 2017

Issue date:

24 Oct 2019